NLE Respiratory Nursing — Acute Respiratory Failure & ARDSStudy Notes

Acute respiratory failure is defined as the inability of the respiratory system to maintain adequate oxygenation and/or ventilation, resulting in critical ABG abnormalities. The two major types are classified by arterial blood gas (ABG) values—a distinction essential for NLE examination success and clinical management. **Type I (Hypoxaemic) Respiratory Failure** occurs when the primary problem is inadequate oxygenation. Defined as PaO2 <60 mmHg on room air at sea level, Type I failure results from conditions that impair oxygen loading into the blood. The pathophysiological mechanisms include: - **Ventilation-Perfusion (V/Q) Mismatch:** Blood perfuses lung tissue with inadequate ventilation, preventing oxygen uptake (e.g., pneumonia, atelectasis, pulmonary edema). Imagine a lung segment receiving blood flow but receiving no fresh air—oxygen cannot cross from alveolus to blood. - **Intrapulmonary Shunting:** Blood bypasses ventilated alveoli entirely, flowing through non-ventilated lung tissue (e.g., ARDS, severe pneumonia). This is the most severe V/Q abnormality and explains why supplemental oxygen may have minimal effect. - **Diffusion Impairment:** The alveolar-capillary membrane is thickened or damaged, slowing oxygen diffusion (e.g., interstitial lung disease, ARDS, pulmonary fibrosis). - **Hypoventilation:** Inadequate air reaching the alveoli (less common in Type I, but occurs with CNS depression or neuromuscular disease). Common causes of Type I failure include pneumonia, ARDS, acute pulmonary edema (cardiogenic or non-cardiogenic), pulmonary embolism, and severe atelectasis. Type I failure is the most common form in critical illness. **Type II (Hypercapnic) Respiratory Failure** occurs when the primary problem is inadequate ventilation—failure to remove carbon dioxide. Defined as PaCO2 >50 mmHg with a pH <7.35 (respiratory acidosis), Type II failure indicates that minute ventilation is insufficient. The pathophysiological mechanisms are centered on reduced ventilation: - **CNS Depression:** Reduced respiratory drive (drug overdose, especially opioids; sedatives; increased intracranial pressure). - **Neuromuscular Disease:** Weakness prevents adequate muscle contraction (Guillain-Barré syndrome, myasthenia gravis, spinal cord injury, diaphragmatic paralysis). - **Chest Wall Abnormalities:** Mechanical restriction (flail chest, severe obesity, kyphoscoliosis, abdominal distension). - **Airflow Obstruction:** COPD exacerbation is the classic example; asthma status asthmaticus also occurs. - **Fatigue:** Exhaustion of respiratory muscles from severe work of breathing (can transition from Type I to Type II). Type II failure is classically seen in COPD exacerbation, drug overdose, and severe asthma. It is more amenable to non-invasive ventilation (BiPAP) because the lungs' intrinsic ability to exchange gas is relatively preserved—the problem is moving air in and out. **Clinical Significance:** The two types require fundamentally different oxygen management. Type I patients tolerate and require high-concentration oxygen to improve PaO2. Type II patients, especially those with chronic CO2 retention (e.g., COPD), can experience **CO2 narcosis** or respiratory depression if given excessive oxygen; they require controlled oxygen (target SpO2 88–92%) and support for ventilation, not just oxygenation.

Early recognition of respiratory failure is critical; the transition can be rapid (minutes to hours). Assessment follows the nursing process and must integrate ABG interpretation with clinical observation. **Early Phase (Acute Hypoxaemia):** The patient exhibits compensatory mechanisms as the body attempts to maintain oxygenation and perfusion. Classic signs include **restlessness, agitation, and anxiety**—the patient feels "something is wrong" even before SpO2 drops significantly. This is driven by hypoxaemia-induced catecholamine release. Accompanying signs are: - **Tachypnea (RR >20/min):** Attempt to increase minute ventilation and blow off CO2. - **Tachycardia (HR >100/min):** Sympathetic response to hypoxaemia and tissue hypoxia. - **Hypertension:** Catecholamine surge increases afterload. - **Diaphoresis:** Sympathetic activation and anxiety. - **Use of accessory muscles:** Intercostal, scalene, and sternocleidomastoid muscles recruited to increase work of breathing. At this stage, many patients are alert and communicative. **A change from baseline mental status—suddenly restless when the patient was calm, or vice versa—is a red flag.** This is especially important in the elderly, post-operative patients, or those on sedatives, where hypoxaemia may manifest subtly as confusion rather than agitation. **Mid Phase (Worsening Hypoxaemia/Hypercapnia):** As gas exchange deteriorates, the patient may become increasingly drowsy or confused. Hypercapnia adds CO2 narcosis (drowsiness from elevated CO2). Cyanosis may become visible (sign of desaturation, though not always present until SpO2 <85%). The patient tires; respiratory rate may paradoxically slow as fatigue sets in. This is an ominous sign—the patient is losing the battle. **Late Phase (Impending Respiratory Arrest):** - **Bradycardia:** Paradoxical slowing (often ominous; indicates severe hypoxaemia and potential cardiac instability). - **Dysrhythmias:** Including bradycardia, atrial fibrillation, or other arrhythmias from severe hypoxia. - **Decreased level of consciousness:** Progressing to unresponsiveness. - **Cyanosis:** Visible darkening of lips, nail beds, ears (sign of severe desaturation). - **Gasping or agonal respirations:** Terminal respiratory pattern. **ABG Interpretation:** The ABG is the gold standard for confirming respiratory failure and determining type. When assessing an ABG, follow this systematic approach: 1. **Check PaO2:** If <60 mmHg on room air (or <70 mmHg on supplemental O2), hypoxaemia is present. 2. **Check PaCO2 and pH together:** If PaCO2 >50 mmHg with pH <7.35, Type II failure (respiratory acidosis) is present. If PaCO2 is normal or low with hypoxaemia, Type I is likely. 3. **Assess respiratory compensation:** In Type I failure, the patient hyperventilates (low PaCO2), driving respiratory alkalosis initially. As fatigue develops, PaCO2 rises—a dangerous sign indicating worsening. 4. **Look at the trend:** Serial ABGs over hours show whether the patient is improving, stable, or deteriorating. Worsening PaO2 despite supplemental oxygen, or rising PaCO2 with falling pH, indicates need for escalation of support. **Supporting Diagnostics:** - **Pulse oximetry (SpO2):** Convenient but can be misleading; pulse ox reads functional hemoglobin saturation and does not reveal PaO2 or PaCO2. A patient with SpO2 92% may have a PaO2 of 60 mmHg (at the edge of failure) or 100 mmHg (acceptable)—ABG clarifies this. - **Chest X-ray:** Identifies the cause (infiltrates for pneumonia/ARDS, hyperinflation for COPD, wedge-shaped infiltrate for PE, whiteout for pulmonary edema). - **Capnography (end-tidal CO2):** Continuous non-invasive trend of ventilation; abnormal waveform can suggest obstruction, neuromuscular fatigue, or tube malpositioning. - **Complete blood count, metabolic panel, lactate:** Assess for anemia (reduces oxygen-carrying capacity), infection, renal/liver dysfunction, and tissue hypoxia. **NANDA Nursing Diagnoses Commonly Applied:** 1. **Ineffective breathing pattern** related to neuromuscular impairment, CNS depression, or increased work of breathing, as evidenced by tachypnea, use of accessory muscles, or ABG abnormality. 2. **Impaired gas exchange** related to ventilation-perfusion mismatch or intrapulmonary shunting, as evidenced by hypoxaemia, tachypnea, or restlessness. 3. **Anxiety** related to hypoxaemia/feeling of impending suffocation, as evidenced by restlessness, agitation, or patient verbalization. 4. **Altered mental status/acute confusion** related to hypoxaemia or hypercapnia, as evidenced by disorientation or decreased responsiveness. **Maslow-Based Prioritization:** Respiratory failure directly threatens physiological safety (oxygen/breathing—the second tier after circulation). Following Maslow, oxygen and ventilation support are the **absolute first priority** before addressing psychosocial concerns or lower-level needs.

ARDS represents a **severe, acute, diffuse inflammatory lung injury** that produces the hallmark feature: **refractory hypoxaemia**—hypoxaemia that does NOT improve adequately with supplemental oxygen alone. This is the single most important distinguishing feature tested on the NLE and is the basis for ARDS diagnosis and the urgency of mechanical ventilation with PEEP. **Pathophysiology—The Leaky Lung:** ARDS begins with a trigger event (most commonly **sepsis**, but also aspiration, trauma, pancreatitis, near-drowning, massive blood transfusion, or severe pneumonia). This trigger initiates a cascade of systemic inflammation. Key steps are: 1. **Alveolar-Capillary Membrane Damage:** The trigger releases inflammatory cytokines (TNF-α, IL-1, IL-6) and activates neutrophils. These agents directly injure the endothelial lining of pulmonary capillaries and the epithelial lining of alveoli, increasing membrane permeability. 2. **Non-Cardiogenic Pulmonary Edema:** Unlike cardiogenic edema (from heart failure), ARDS edema results from a leaky membrane, not elevated hydrostatic pressure. Protein-rich fluid floods the alveoli. The pulmonary capillary wedge pressure (PCWP) on Swan-Ganz catheter is **normal** in ARDS—this is the diagnostic distinction from heart failure. 3. **Surfactant Loss and Alveolar Collapse:** Surfactant (a lipid-protein mix that reduces surface tension) is inactivated or washed away by the edema fluid. Alveoli collapse (atelectasis). Lung compliance plummets—the lungs become "stiff," requiring high pressures to inflate. The work of breathing increases dramatically, and the patient rapidly fatigues. 4. **Severe V/Q Mismatch and Shunting:** Collapsed, fluid-filled alveoli do not participate in gas exchange. Blood that perfuses these alveoli is shunted—oxygen cannot reach it, no matter how much supplemental oxygen is given. This explains the **refractory hypoxaemia**. Even with FiO2 1.0 (100% oxygen), PaO2 may remain <60 mmHg. 5. **Progression to Fibrosis (Late Phase):** If ARDS persists, inflammatory cells and fibroblasts proliferate, leading to lung fibrosis in survivors—a long-term complication. **Clinical Presentation and Course:** ARDS typically develops **acutely within the first few hours to days** after the triggering event. The patient presents with: - **Severe, progressive dyspnea** and tachypnea (often RR >30/min). - **Refractory hypoxaemia:** Despite high-flow oxygen or even 100% FiO2, PaO2 remains low (<60 mmHg). A **PaO2/FiO2 ratio <300** is part of the diagnostic criteria. - **Restlessness, anxiety, and use of all accessory muscles** as the patient struggles to breathe. - **Diffuse bilateral crackles** on lung auscultation. - **Rapid clinical deterioration** within hours to a day or two post-trigger. The patient's own efforts to breathe become counterproductive. Hypoxaemia-driven catecholamine release causes tachycardia and vasoconstriction. Hypercapnia may develop if the patient tires. Multi-organ dysfunction often ensues (sepsis-related organ failure, acute kidney injury, disseminated intravascular coagulation). **Diagnostic Findings:** **Chest X-ray (CXR):** The classic finding is **diffuse bilateral "white-out" infiltrates**, described as a "ground-glass" or "snow-storm" appearance. Both lungs are involved symmetrically. Importantly, **no focal consolidation or pneumothorax is present**—it is a diffuse process. Early CXRs may appear deceptively normal (within 6–24 hours of onset), so clinical suspicion and ABG must guide diagnosis. **ABG (Arterial Blood Gas):** - **Early:** Respiratory alkalosis (PaCO2 <35 mmHg, pH >7.45) from hyperventilation. The patient is "blowing off" CO2 in an attempt to maintain PaO2. - **Progressive:** Worsening hypoxaemia (PaO2 drops despite supplemental O2). Lactate rises from tissue hypoxia. - **Late/Fatigue:** Respiratory acidosis (PaCO2 >50 mmHg, pH <7.35) as the patient tires. This is an ominous sign—the patient can no longer compensate. **PaO2/FiO2 Ratio (P/F Ratio):** Calculated as PaO2 divided by FiO2 expressed as a decimal. For example, if PaO2 is 50 mmHg on FiO2 0.8 (80%), the P/F = 50/0.8 = 62.5. A P/F <300 is diagnostic of ARDS and reflects the severity of the oxygenation defect. **Pulmonary Capillary Wedge Pressure (PCWP):** If a Swan-Ganz catheter is in place, PCWP is **normal or low** (<18 mmHg), confirming the edema is non-cardiogenic. This is the definitive distinction from heart failure. **Diagnostic Criteria (Berlin Definition, 2012—commonly referenced):** 1. **Acute onset** within 1 week of a known trigger or new worsening of respiratory symptoms. 2. **Bilateral opacities** on imaging (CXR or CT) not fully explained by effusions, collapse, or nodules. 3. **Oxygenation defect:** PaO2/FiO2 ≤300 mmHg (at sea level, with PEEP ≥5 cmH2O or non-invasive ventilation equivalent). 4. **Origin of edema:** Not primarily cardiac; if cardiac risk factors present, PCWP ≤18 mmHg or no clinical evidence of cardiac dysfunction. **Nursing Management and Priority Interventions:** **Oxygenation and Ventilation Support:** Nearly 100% of ARDS patients require **intubation and mechanical ventilation**. The rationale is twofold: (1) to deliver high FiO2 and PEEP invasively, and (2) to rest the respiratory muscles, preventing fatigue and collapse. **PEEP (Positive End-Expiratory Pressure):** This is the **cornerstone of ARDS management**. PEEP is a pressure held at the end of expiration, preventing alveolar collapse. Collapsed alveoli are "recruited" back open, improving oxygenation. Typical PEEP in ARDS ranges from 5–20 cmH2O, titrated to maintain adequate oxygenation while minimizing hemodynamic compromise. - **Mechanism:** At the end of a normal breath, the lungs deflate to functional residual capacity (FRC). In ARDS, many alveoli collapse (close) at this point because surfactant is lost and the recoil pressure is high. PEEP prevents this collapse by maintaining positive pressure throughout the respiratory cycle. - **Clinical effect:** PEEP improves PaO2 and SpO2, allowing reduction in FiO2 (which reduces oxygen toxicity risk). - **Adverse effects:** Excessive PEEP can reduce venous return (decreasing cardiac preload and blood pressure) and risks **barotrauma**—rupture of alveoli, leading to pneumothorax or pneumomediastinum. Monitor hemodynamics and watch for sudden deterioration. **Lung-Protective Ventilation (LPV):** The goal is to prevent further lung injury from mechanical ventilation itself (ventilator-induced lung injury). Key principles: 1. **Low Tidal Volumes (Vt ~6 mL/kg of predicted body weight):** A landmark 2000 ARDS Network trial showed that limiting Vt to 6 mL/kg (compared to the older standard of 12 mL/kg) reduced mortality by ~22%. The smaller volumes prevent overdistension and volutrauma. Calculate predicted body weight using: Males = 50 + 2.3 × (height in inches − 60); Females = 45.5 + 2.3 × (height in inches − 60). For example, a 5'8" (68 inches) male would have predicted weight ≈ 50 + 2.3 × 8 = 68.4 kg; Vt target = 6 × 68.4 ≈ 410 mL. 2. **Plateau Pressure Limit:** Maintain plateau pressure <30 cmH2O to prevent alveolar overdistension. Plateau pressure is measured by an inspiratory hold on the ventilator—it reflects the static recoil pressure of the lungs and chest wall. 3. **Permissive Hypercapnia:** Accept higher PaCO2 (up to 80 mmHg) if it prevents further lung injury. The pH target is >7.15. This is a paradigm shift for nurses accustomed to "normalizing" CO2; in ARDS, some CO2 retention is acceptable if it means using smaller volumes. 4. **Appropriate PEEP:** Use PEEP sufficient to keep alveoli open but not excessive. **Prone Positioning:** Positioning the patient **prone (face-down)** for 12–16 hours per day improves oxygenation significantly in **moderate-to-severe ARDS** (P/F <150). The mechanism is improved V/Q matching—the dependent (lower) lung zones, which are normally least ventilated, become better ventilated in the prone position. The prone patient requires careful management to prevent pressure injuries, maintain lines (endotracheal tube, central lines), and allow proper assessment. Proning is labor-intensive but can be a life-saving intervention, sometimes preventing the need for ECMO (extracorporeal membrane oxygenation). **Hemodynamic Support:** Ensure adequate perfusion. ARDS patients often have sepsis or other causes of shock. Use vasopressors (norepinephrine) if needed to maintain MAP ≥65 mmHg; judicious IV fluid resuscitation (avoiding fluid overload, which worsens pulmonary edema); and inotropes if cardiac dysfunction coexists. **Treat the Underlying Cause:** - **Sepsis:** Blood cultures, broad-spectrum antibiotics (e.g., ceftriaxone + gentamicin for community-acquired, with escalation for hospital-acquired pathogens), source control (drainage, debridement as needed). - **Aspiration:** Suction, antibiotics if aspiration pneumonia develops. - **Trauma:** Surgery, stabilization, pain control. - **Pancreatitis:** Supportive care, ERCP if biliary obstruction. - **Transfusion reaction:** Stop transfusion, supportive care. **Nursing Care Specifics:** - **Monitor ABGs serially** (initially q2–4h, then daily once stabilized) to track oxygenation trends and guide FiO2/PEEP adjustments. - **Implement VAP prevention bundle** (see Mechanical Ventilation section below). - **Sedation and analgesia:** Keep the patient comfortable (often propofol or midazolam + fentanyl or morphine) to prevent fighting the ventilator and reduce metabolic demand. - **Nutritional support:** Start enteral feeding early if the patient tolerates (reduces bacterial translocation and maintains gut integrity); use lower-calorie, lower-carbohydrate feeds to reduce CO2 production. - **Renal replacement therapy:** If acute kidney injury develops (common in ARDS), provide CVVH (continuous veno-venous hemofiltration) or CRRT as indicated. - **Prevent complications:** DVT prophylaxis (compression stockings, pharmacological if no contraindication), stress-ulcer prophylaxis (H2-blocker or PPI), skin care, and eye care for the sedated patient. - **Family communication:** ARDS is frightening; explain the disease, the ventilator, the plan, and realistic prognosis. Family-centered care is crucial. **Complications and Prognosis:** **Short-term complications:** Barotrauma (pneumothorax, pneumomediastinum, subcutaneous emphysema), ventilator-associated pneumonia (VAP), acute kidney injury, cardiac arrhythmias, multi-organ failure, and death. **Long-term complications (survivors):** Pulmonary fibrosis, persistent dyspnea, reduced exercise tolerance, cognitive impairment (post-ICU delirium), and psychological sequelae (PTSD). **Mortality:** Approximately 35–50% depending on the cause and patient factors (older age, sepsis, non-pulmonary organ failure = worse prognosis). Survivors often require weeks of ICU care and prolonged weaning from mechanical ventilation. **Weaning and Recovery:** Once the underlying cause is controlled and oxygenation improves (P/F >200, PEEP ≤5, FiO2 ≤0.4), weaning can begin. The process is gradual—reduce PEEP incrementally, reduce FiO2, assess spontaneous breathing trials (SBT), and eventually extubate. Post-extubation, pulmonary rehabilitation is essential to recover respiratory and physical function.

Pulmonary embolism is an **acute obstruction of the pulmonary artery or its branches**, most commonly by a **venous thrombus that dislodges from a deep vein of the leg or pelvis (DVT) and lodges in the lungs**. PE is a life-threatening emergency and a **major cause of preventable hospital mortality**—making PE recognition and prevention heavily emphasized in nursing education and the NLE. **Pathophysiology:** The path to PE begins with thrombus formation in a peripheral vein, usually the deep veins of the lower extremity (popliteal, femoral, iliac) or rarely the pelvic veins. The thrombus dislodges (embolizes) and travels through the venous system to the right heart. It then lodges in the pulmonary artery or a branch, partially or completely obstructing blood flow. **Hemodynamic consequences depend on the size of the thrombus and the pulmonary vascular reserve:** - **Small PE (low-risk):** Lodges in a distal pulmonary artery branch; may be clinically silent or cause minimal symptoms. The patient may compensate well initially. - **Massive PE (high-risk):** Obstructs the main pulmonary artery or multiple large branches. Acute right ventricular strain ensues, cardiac output drops, systemic hypotension develops, and the patient may have cardiogenic shock or cardiac arrest ("sudden death" scenario, famously seen in airline passengers or post-operative patients). **Types of Emboli (less common than thrombi, but testable):** - **Thrombus (99% of PEs):** From DVT as above. - **Fat embolus:** Post-fracture, post-orthopedic surgery; fat from bone marrow enters disrupted bone vessels. - **Air embolus:** Central line placement, disconnected IV, decompression (diving). - **Amniotic fluid embolus:** Rare, during labor/delivery (obstetric emergency). - **Tumor thrombus:** Rarely, from malignancy. **Virchow's Triad—The Risk Framework:** Rudolph Virchow identified three conditions that promote thrombosis. Recognizing these is essential for identifying at-risk patients and implementing prevention: 1. **Venous Stasis (Blood Flow Slowed):** - Immobilization (bed rest, long flights, long car rides, post-operative) - Atrial fibrillation (irregular rhythm slows flow) - Heart failure, severe respiratory disease - Obesity, abdominal mass 2. **Hypercoagulability (Blood Clots More Easily):** - Malignancy (cancer cells release thromboplastic substances; also chemotherapy) - Pregnancy and postpartum period (physiological hypercoagulability; estrogen increases clotting factors) - Oral contraceptives and hormone replacement therapy (estrogen dose-dependent) - Smoking - Dehydration - Inherited thrombophilia (Factor V Leiden, prothrombin gene mutation, antithrombin deficiency) - Antiphospholipid syndrome - Recent surgery or trauma 3. **Endothelial Injury (Vessel Wall Damage):** - Trauma (fracture, crush injury) - Surgery (especially orthopedic: hip/knee replacement, major surgery) - Central venous catheter placement or presence - Invasive procedures (angiography, venography) - Acute MI - Previous DVT or PE **Risk Stratification:** Many hospitals use a risk assessment tool (e.g., Padua Prediction Score, Geneva Risk Score) to identify high-risk patients and guide prophylaxis decisions. **Clinical Presentation:** PE presentation is highly variable, depending on the size and location of the thrombus and the patient's cardiopulmonary reserve. **Suspicion is key—many patients have atypical presentations.** **Classic Presentation (Small-to-Moderate PE):** - **Sudden dyspnea:** Often the first symptom; the patient may be at rest or on minimal activity. - **Pleuritic chest pain:** Sharp, worse with deep breathing or coughing; suggests a distal PE affecting the pleura. - **Tachypnea and tachycardia:** RR >20/min, HR >100/min. - **Anxiety and sense of impending doom:** Related to acute hypoxaemia and catecholamine release. - **Syncope or near-syncope:** If the PE causes acute right ventricular strain or arrhythmia. **Other signs:** - Haemoptysis (coughing blood): indicates pulmonary infarction from distal PE; less common. - Low-grade fever (often <38.5°C). - Signs of DVT in the leg (unilateral calf swelling, warmth, tenderness, redness)—present in ~50% of PE patients. **Massive PE (High-Risk—Cardiogenic Shock):** - Sudden severe dyspnea and chest pain. - **Hypotension (SBP <90 mmHg or drop >40 mmHg from baseline):** From acute right ventricular failure. - **Cyanosis:** From severe hypoxaemia and stagnant blood flow. - **Syncope or cardiac arrest:** From cardiogenic shock. - **Signs of right heart strain:** elevated JVP (distended neck veins), prominent right ventricular heave. - **Acute arrhythmia:** Atrial fibrillation or sinus tachycardia (>100/min). **Atypical/Subtle Presentations (Common in Post-operative or Elderly Patients):** - Isolated tachycardia without respiratory symptoms. - Confusion or delirium (from hypoxaemia). - Vague dyspnea attributed to pain or anesthesia. - Unexplained hypoxemia on pulse oximetry. - Gradual desaturation over hours (post-operative setting). **Diagnostic Evaluation:** **Clinical Scoring (to assess pre-test probability):** Tools like the **Wells PE Scoring System** use clinical features to categorize patients as low, intermediate, or high probability, guiding further testing: - **High-risk features:** Tachycardia, hypoxia, hypotension, signs of DVT, or prior PE/cardiopulmonary disease. - **Low-risk features:** Young age, no risk factors, normal vitals, no dyspnea. **D-Dimer (Fibrin Degradation Product):** A highly sensitive but **not specific** test. D-dimer is elevated whenever there is thrombin and fibrin formation (DVT, PE, MI, sepsis, trauma, surgery, inflammation). - **If D-dimer is NORMAL:** PE is essentially ruled out in low-risk patients; no further imaging needed. - **If D-dimer is ELEVATED:** Does not confirm PE; must proceed to imaging. - **Limitation:** D-dimer is often elevated in hospitalized/ICU patients, elderly patients, and post-op patients, reducing its specificity. **CT Pulmonary Angiography (CTPA):** The **gold-standard confirmatory test** in most settings. High-resolution CT with IV contrast shows the pulmonary arteries. A thrombus appears as a filling defect (contrast void) within an artery. CTPA is sensitive, specific, and can visualize segmental and smaller branches. Assess for: - Thrombus location (main, lobar, segmental, subsegmental). - Right ventricular dysfunction (RV dilation, septal bowing, reflux of contrast into IVC). - Infarction (wedge-shaped peripheral consolidation). **Ventilation-Perfusion (V/Q) Scan:** Alternative if CTPA is contraindicated (e.g., contrast allergy, renal failure). Detects areas of ventilation-perfusion mismatch. Less sensitive than CTPA; interpretation can be complex. **ABG (Arterial Blood Gas):** - **Hypoxaemia with hypocapnia (low PaCO2):** Respiratory alkalosis from hyperventilation. PaO2 is often <80 mmHg (sometimes <60 mmHg in significant PE). - A **normal ABG does NOT rule out PE**; ~20% of PE patients have normal ABG, especially if the PE is small. - **Alveolar-arterial oxygen gradient (A-a gradient) >15 mmHg** suggests PE or other cardiopulmonary disease. **12-Lead ECG:** - Usually non-specific; tachycardia and non-specific ST/T wave changes are common. - The classic **"S1Q3T3" pattern** (S wave in lead I, Q wave in lead III, inverted T in lead III) is seen in <10% of PE patients; when present, it suggests massive PE with right heart strain, but absence does NOT rule out PE. - May show atrial fibrillation, right axis deviation (massive PE), or signs of right ventricular strain. **Troponin and BNP (B-type Natriuretic Peptide):** - Elevated in massive PE with right ventricular strain; useful for risk stratification. - Normal does not rule out PE. **Echocardiography (Ultrasound of Heart):** - Useful to assess right ventricular function in hemodynamically unstable patients. - May show RV dilation, RV-to-LV dimension ratio >0.9, or RV dysfunction. - Not used to diagnose PE itself (cannot visualize pulmonary arteries directly). **Nursing Assessment and Priority Interventions:** **Immediate (First Few Minutes):** 1. **POSITION:** Elevate the head of the bed 30–45°. Upright positioning eases dyspnea and improves oxygenation. 2. **OXYGEN:** Deliver high-flow oxygen immediately (non-rebreather mask targeting SpO2 >94%, or as prescribed). Hypoxaemia must be corrected. 3. **ASSESSMENT:** Obtain vital signs (note hypotension, which indicates massive PE and hemodynamic instability). Assess for dyspnea, chest pain, cyanosis, and signs of DVT. Place on continuous pulse oximetry and cardiac monitoring. 4. **STAY WITH THE PATIENT:** Do not leave an anxious, hypoxic patient alone. The sense of impending doom is real; reassurance is therapeutic. 5. **NOTIFY THE PHYSICIAN IMMEDIATELY:** PE is a medical emergency. Do not delay. 6. **IV ACCESS AND BLOODS:** Establish two IV lines, draw blood for labs (CBC, metabolic panel, troponin, D-dimer, type & cross if thrombolysis is considered), and send for ABG and CTPA. **Ongoing Management:** **Anticoagulation (The Mainstay):** The goal is to **prevent thrombus propagation** and formation of new thrombi, allowing the body's fibrinolytic system to gradually dissolve the existing clot. Most PE patients are anticoagulated even before CTPA confirms the diagnosis if clinical suspicion is high (not delaying for imaging). **Heparin (Unfractionated IV Heparin):** - **Loading dose:** 80 units/kg IV bolus. - **Maintenance:** 18 units/kg/hr IV infusion, adjusted to maintain aPTT 1.5–2.5 times control (usually 60–80 seconds). - **Onset:** Immediate (minutes). - **Monitoring:** aPTT baseline, 6 hours after loading, 6 hours after rate change, then daily when stable. - **Antidote:** Protamine sulfate (slowly IV) binds heparin and reverses its effect within minutes; use if major bleeding occurs. - **Risk:** Heparin-induced thrombocytopenia (HIT)—a paradoxical prothrombotic state caused by anti-PF4/heparin antibodies. Monitor platelets; if they drop >50% or new thrombosis develops, **stop heparin immediately** and switch to a direct thrombin inhibitor (e.g., argatroban or fondaparinux). - **Advantages:** Rapid onset, easy to reverse, suitable for renal/hepatic disease. **Low-Molecular-Weight Heparin (LMWH—Enoxaparin):** - **Dosing:** 1 mg/kg subcutaneously every 12 hours (or 1.5 mg/kg daily); no loading dose needed. - **Onset:** Within 2–4 hours. - **Monitoring:** Usually **no routine aPTT monitoring** (LMWH has predictable pharmacokinetics); but monitor baseline platelet count for HIT risk. - **Antidote:** Protamine sulfate partially reverses (less complete reversal than for unfractionated heparin). - **Advantages:** Predictable dosing, subcutaneous, convenient for outpatient. - **Disadvantages:** Longer half-life (harder to reverse); reduced clearance in renal failure (creatinine clearance <30 mL/min). **Transition to Warfarin (Vitamin K Antagonist):** After initial parenteral heparin (unfractionated or LMWH), most patients transition to **warfarin** for long-term (3–6 months or longer, depending on PE context) anticoagulation. - **Mechanism:** Inhibits vitamin K-dependent clotting factors (II, VII, IX, X). - **Onset:** Delayed (2–7 days); there is a transient hypercoagulable state initially as Factor VII (which has a short half-life) falls before Factors II, IX, X. Overlap with heparin for 5–7 days until INR therapeutic. - **Target INR:** 2.0–3.0 for PE/DVT (INR is the normalized PT ratio; measured via PT blood test). - **Monitoring:** PT/INR baseline, at 3–5 days after starting, then weekly × 1–2, then monthly. - **Antidote:** Vitamin K (phytonadione), which restores synthesis of vitamin K-dependent factors; takes 12–24 hours (slow) for effect. For rapid reversal (major bleeding): Fresh Frozen Plasma (FFP) or Prothrombin Complex Concentrate (PCC) provides immediate factors. - **Risks:** Over-anticoagulation (INR >4) increases bleeding risk; sub-therapeutic INR allows thrombus progression. - **Drug interactions:** Many drugs affect warfarin metabolism (e.g., NSAIDs increase bleeding, rifampin and some antibiotics decrease INR). Teach patient to **report new medications to the anticoagulation clinic**. - **Dietary vitamin K:** Warfarin antagonizes vitamin K, so large increases or decreases in dietary vitamin K (green leafy vegetables, cruciferous vegetables, soy, some herbal supplements) alter INR. Counsel **consistent vitamin K intake** (not avoiding it, but keeping it steady). - **Lifestyle:** Avoid alcohol excess, use electric razor and soft toothbrush, avoid contact sports, report unusual bleeding. **Direct Oral Anticoagulants (DOACs):** Increasing use in PE management. These are **Factor Xa inhibitors** (rivaroxaban, apixaban, edoxaban) or **direct thrombin inhibitors** (dabigatran). - **Advantages:** Fixed oral dosing (no monitoring), rapid onset, fewer drug interactions than warfarin, more predictable pharmacokinetics. - **Disadvantages:** Higher cost, no proven reversal agent (except idarucizumab for dabigatran), cannot be used in severe renal disease (most require CrCl >30 mL/min), not suitable for some situations (e.g., antiphospholipid syndrome). - **Monitoring:** Generally none required; baseline renal function important. - **Teaching:** Take at the same time daily; do not skip doses; some (rivaroxaban, apixaban) taken with food. **Thrombolysis (Clot Dissolution):** Reserved for **massive PE with hemodynamic instability** (hypotension, cardiogenic shock, cardiac arrest). - **Agents:** Alteplase (tissue plasminogen activator, t-PA), streptokinase, urokinase. - **Mechanism:** Enzymatically activate plasminogen to plasmin, which degrades fibrin and dissolves the thrombus. - **Risks:** Significant bleeding (intracranial hemorrhage, GI bleed, retroperitoneal bleed); higher than anticoagulation alone. Contraindications: recent surgery, bleeding, head trauma, CNS disease. - **Success:** Hemodynamically unstable patients benefit most; mortality reduction ~10% in massive PE. - **NOT used in stable/sub-massive PE** due to bleeding risk outweighing benefit. **Inferior Vena Cava (IVC) Filter:** A mechanical device placed percutaneously into the IVC to catch emboli before they reach the lungs. Used **when anticoagulation is contraindicated** (active bleeding, intracranial hemorrhage, severe thrombocytopenia) or when PE develops despite anticoagulation. - **Advantages:** Prevents PE without systemic anticoagulation. - **Disadvantages:** Does not prevent new thrombus formation (so anticoagulation should be resumed once safe); increases DVT risk; can thrombose or perforate the IVC. - **Not used routinely** in PE; reserved for specific indications. **Hemodynamic Support:** In massive PE with hypotension: - IV fluids (cautious; not aggressive, as right ventricle is straining). - Vasopressors (norepinephrine) to maintain MAP ≥65 mmHg. - Inotropes (dobutamine) if RV output is impaired. - Oxygen to maintain SpO2 >90%. - Monitor with central venous pressure (CVP) line and consider Swan-Ganz catheter if available. **Nursing Interventions—Ongoing:** - **Monitor anticoagulation levels** (aPTT if heparin, INR if warfarin, baseline platelet count for HIT monitoring). - **Watch for signs of bleeding:** Bruising (especially petechiae), bleeding gums, hemoptysis, hematuria, melena, hematemesis. Teach patient the same. - **Minimize invasive procedures:** Avoid intramuscular injections, use gentle IV technique. - **Encourage leg elevation and mild activity** to promote venous return and reduce DVT risk. - **Teach patient the importance of compliance** with anticoagulation (not missing doses, keeping clinic appointments for INR monitoring). - **Educate on signs of recurrent PE:** Sudden dyspnea, chest pain, syncope—seek medical attention immediately. - **Document baseline bleeding risk:** Renal/hepatic function, drug interactions, patient understanding. **PE Prevention—Heavily Tested on NLE:** Prevention is a core nursing responsibility, especially in hospitalized patients. The **Joanna Briggs Institute and ACCP guidelines** recommend: **For All Hospitalized Patients:** 1. **Early and frequent mobilization:** Get patients out of bed as soon as medically safe (post-op, even day 1 if possible). Ambulation or passive leg exercises stimulate calf muscle pump and prevent stasis. 2. **Compression devices (mechanical prophylaxis):** - **Compression stockings (graduated compression):** Class III (highest compression) TED hose. Improve venous return from the legs. Patient education is key—stockings must be applied correctly (no wrinkles), kept clean, and removed daily for skin inspection. - **Intermittent pneumatic compression (IPC):** Boots that inflate/deflate cyclically, massaging the leg. Highly effective; used especially when pharmacological prophylaxis is contraindicated. 3. **Hydration:** Adequate fluid intake maintains blood viscosity and flow. Encourage oral intake; provide IV fluids in NPO patients. 4. **Leg exercises:** Ankle circles, calf pumps ("march in place" while seated), and deep breathing (promotes venous return via negative thoracic pressure). **For High-Risk Patients (Post-op, Immobile, Cancer, Fracture, Major Surgery):** **Pharmacological Prophylaxis:** - **LMWH (Enoxaparin 40 mg daily SC):** Standard for post-op and hospitalized high-risk patients; given for 7–35 days depending on risk. - **Unfractionated heparin 5000 units SC every 8–12 hours:** If renal failure (LMWH is cleared by kidneys). - **Fondaparinux (Factor Xa inhibitor):** Alternative to LMWH; 2.5 mg SC daily. - **Warfarin:** Used for extended prophylaxis in some high-risk patients (e.g., hip replacement). **Duration:** Typically 7–10 days for general surgery, up to 35 days for hip/knee surgery. **Monitoring for Prophylaxis:** No routine aPTT or INR needed for prophylactic doses. Monitor for signs of bleeding, and maintain vigilance for HIT if patient is on heparin. **Special Considerations in Philippine Healthcare Context:** In many Philippine hospitals, availability of some anticoagulants (e.g., DOACs) may be limited due to cost. Nurses must be familiar with **heparin and warfarin**, which are universally available. Knowledge of **transitioning from heparin to warfarin**, managing INR, and educating patients on dietary vitamin K and drug interactions is essential. In resource-limited settings, **mechanical prophylaxis (compression, early mobilization)** may be emphasized.

Mechanical ventilation is a **life-saving intervention** for patients who cannot maintain adequate oxygenation or ventilation on their own. As a nurse caring for ventilated patients, your role is to ensure the tube is properly positioned and secured, monitor the ventilator function and ABG trends, implement the ventilator-associated pneumonia (VAP) prevention bundle, respond appropriately to alarms, and provide comfort care for the sedated patient. Understanding basic ventilator terms and troubleshooting common problems is essential for NLE success and patient safety. **When is Mechanical Ventilation Indicated?** - **Type I respiratory failure** refractory to supplemental oxygen (ARDS, severe pneumonia, pulmonary edema, PE). - **Type II respiratory failure** with pH <7.25 or failing non-invasive ventilation (COPD exacerbation, drug overdose, neuromuscular disease). - **Airway protection:** GCS ≤8 (cannot protect airway from aspiration; intubate to secure airway). - **Severe dyspnea or stridor** from upper airway obstruction. - **Apnea or gasping respirations** (terminal respiratory pattern). - **Exhaustion and declining ABG** despite non-invasive support (e.g., BiPAP failing, patient tiring). **The Endotracheal Tube (ETT) and Intubation:** Most acute intubations are **orotracheal** (tube through the mouth into the trachea), which allows a larger diameter tube and easier visualization. Some patients have **nasotracheal** intubation (through the nose), which is more comfortable long-term but narrower tube diameter. **Tracheostomy** (surgical/percutaneous placement of a tube directly into the trachea) is reserved for patients expected to be ventilated >2–3 weeks. **ETT Confirmation and Positioning:** 1. **Immediate (in the OR/ICU after intubation):** - **Auscultation:** Listen for breath sounds **bilaterally and equally** over both lungs; if sounds are louder on the right, the tube is too far down (right mainstem intubation), and the left lung is under-ventilated (risk of atelectasis and hypoxemia). - **Capnography (End-Tidal CO2):** A capnograph attached to the ETT detects CO2 in exhaled gas. Presence of CO2 confirms tracheal (not esophageal) placement. The waveform shows a characteristic square-wave pattern; abnormalities (no waveform, low ETCO2) suggest tube malposition or equipment failure. - **Chest X-ray:** The gold standard for confirming tube position. The tube tip should be **2–3 cm above the carina** (the bifurcation of the trachea into right and left mainsttem bronchi). Position is noted by the tip of the tube relative to the carina or vertebral level (typically C5 or T1 level on CXR). - **Visual inspection:** Note the depth marking on the tube (usually 21 cm at the lips for adults), and mark it with a pen or tape so you can detect inadvertent movement. 2. **Ongoing (throughout ventilation):** - Regularly recheck bilateral breath sounds and capnography waveform. - If breath sounds suddenly become unequal or absent on the left, suspect **right mainstem intubation** (tube slipped down). Pull the tube back 1–2 cm, recheck breath sounds and capnography, and confirm with CXR. - A sudden **loss of ETCO2 waveform** suggests tube dislodgement or obstruction; immediately assess the patient and the tube. **ETT Securing and Maintenance:** - **Secure the tube** firmly with tape or a commercial holder to prevent accidental extubation (which is an emergency). - **Inspect the mouth/nose area daily** for skin breakdown from the tape. - **Subglottic suctioning** (if the ventilator has a port): Removes secretions pooled above the cuff, reducing VAP risk. - **Cuff pressure:** The ETT has an inflatable balloon (cuff) that seals the airway. Monitor **cuff pressure** regularly (target 25–30 cmH2O); under-inflation allows aspiration around the cuff, over-inflation causes tracheal ischemia. Check cuff pressure before and after prone positioning, position changes, and if the patient is agitated (biting the tube increases cuff pressure). - **Oral/nasal care:** Brush teeth if orotracheal; saline rinses; inspect for sores. **Key Ventilator Terms and Settings:** **FiO2 (Fraction of Inspired Oxygen):** The percentage of oxygen in the inspired gas mixture. Room air is 21% FiO2; mechanical ventilators deliver 21–100% (1.0). - **Initial FiO2:** Usually started at 1.0 (100%) to ensure oxygenation during acute illness, then **weaned down** based on SpO2 and ABG. - **Target SpO2:** Generally 90–95% (but COPD/CO2 retainers target 88–92% to avoid suppressing respiratory drive). - **Oxygen toxicity:** Prolonged exposure to high FiO2 (>0.5) causes reactive oxygen species damage (tracheitis, reduced surfactant, ARDS-like picture). Wean FiO2 to the **lowest level that maintains adequate SpO2**. **PEEP (Positive End-Expiratory Pressure):** Positive pressure maintained at the end of expiration. PEEP is **the cornerstone of oxygenation support in ARDS** and is crucial for recruiting and keeping alveoli open. - **Starting PEEP:** Often 5 cmH2O; escalated in ARDS (target 10–20 cmH2O depending on severity and oxygenation response). - **Mechanism:** Prevents alveolar collapse at the end of expiration, recruits collapsed alveoli, improves oxygenation and ventilation-perfusion matching. - **Adverse effects:** - **Reduced venous return:** Positive intrathoracic pressure reduces blood return to the heart, decreasing cardiac preload and cardiac output. Monitor blood pressure; if hypotension develops with PEEP escalation, may need fluid bolus or vasopressor. - **Barotrauma:** Excessive PEEP over-distends alveoli, risking rupture (pneumothorax, pneumomediastinum, subcutaneous emphysema). Watch for sudden deterioration, asymmetric breath sounds, or high peak airway pressures. - **Auto-PEEP (intrinsic PEEP):** In obstructive disease (COPD, asthma), air becomes trapped in the lungs (incomplete exhalation). This unmeasured, **self-generated PEEP** can exceed the set PEEP and cause alveolar over-distension. Manage by: prolonging expiration time, reducing respiratory rate, and using bronchodilators. **Tidal Volume (Vt):** The volume of air delivered with each breath. - **Traditional setting:** 10–15 mL/kg (largely abandoned due to volutrauma). - **Lung-protective setting (ARDS):** 6–8 mL/kg of **predicted body weight**, not actual body weight. Prevents volutrauma. - **Monitoring:** Watch for excessive peak pressures (>30 cmH2O suggests excessive Vt or increased lung stiffness); if pressures are high, reduce Vt slightly, ensure proper sedation (patient not fighting vent), and assess for obstruction (secretions, kink, biting tube). **Respiratory Rate:** - **Initial:** Usually 12–16 breaths/min for adults; adjusted based on ABG (if too low, PaCO2 rises; if too high, hypocapnia may occur). - **Patient synchronization:** If the patient's own rate is much higher than the set rate, the patient is "fighting the vent"—increase sedation or switch to an assisted mode. **Ventilator Modes (Simplified):** 1. **Controlled Mechanical Ventilation (CMV) or Assist-Control (AC):** The ventilator delivers a **set number of breaths at a set tidal volume**. If the patient triggers a breath (detected by a slight drop in pressure or flow), the ventilator delivers the full set Vt. This is commonly used in sedated patients or those who are severely ill. 2. **Synchronized Intermittent Mandatory Ventilation (SIMV):** The ventilator delivers a **set number of mandatory breaths**, but the patient can take additional "spontaneous" breaths (at their own rate and Vt) between the mandatory breaths. Useful during weaning because it allows gradual increase in patient work. 3. **Pressure Support Ventilation (PSV):** The ventilator delivers **pressure (not volume)**; the patient triggers each breath, and the vent provides a preset pressure level to assist the breath. The Vt depends on how hard the patient works and lung compliance. Used during weaning; requires patient to have an adequate respiratory drive. **Peak Airway Pressure and Plateau Pressure:** - **Peak Pressure:** The maximum pressure in the airways during inspiration. Elevated peak pressure suggests obstruction (secretions, tube kink, bronchospasm) or reduced lung compliance. - **Plateau Pressure:** Measured by an inspiratory hold maneuver; reflects static compliance of the lungs and chest wall. In ARDS, target plateau <30 cmH2O to prevent volutrauma. **Alarms—Critical to Understand:** **High-Pressure Alarm (Peak Pressure >25–35 cmH2O, varies by setting):** Common causes ("SOCKS" mnemonic—Secretions, Obstruction, Coughing/biting, Kink, Spasm/bronchospasm): 1. **Secretions:** Mucus obstructing the ETT. **Action: Suction the airway.** Hyperoxygenate before suctioning (to prevent hypoxemia during the procedure), pass the suction catheter gently, apply suction only during withdrawal, and limit each pass to ~10–15 seconds. Do NOT perform routine suctioning on a schedule; suction only as needed (when crackles are heard or ventilator pressure increases). 2. **Obstruction:** Tube kinked, bitten, or turned. **Action: Assess tubing, reposition patient's head, check for biting (sedation may need increase), look for a kink in the tubing.** 3. **Coughing/Fighting the Vent:** Patient is conscious and triggering breaths or resisting the ventilator. **Action: Assess for pain, discomfort, or anxiety; increase sedation/analgesia as needed. Ensure the patient is synchronized with the vent.** 4. **Bronchospasm:** Acute airway constriction. **Action: Listen for wheezing; administer bronchodilators (albuterol nebulizer or MDI) and corticosteroids if asthma or COPD exacerbation.** 5. **Pneumothorax:** Air in the pleural space (from barotrauma). **Action: Assess for unequal breath sounds, sudden dyspnea, hypotension; call physician urgently; chest X-ray and possibly chest tube placement.** **If you cannot quickly identify and fix the high-pressure alarm:** **DISCONNECT THE VENT and manually ventilate the patient with the bag-valve-mask (ambu bag) while calling for help.** This ensures the patient is oxygenated and ventilated while the problem is being assessed. **Low-Pressure Alarm (usually <5 cmH2O change from baseline):** Suggests a **leak or disconnection**. Causes: 1. **Disconnected tubing:** Circuit disconnected from the ETT, ventilator outlet, or humidifier. **Action: Trace the entire circuit, reconnect any loose parts.** 2. **Leaking cuff:** ETT cuff under-inflated (patient can breathe around it, air escapes). **Action: Check cuff pressure with manometer, inflate as needed to 25–30 cmH2O.** 3. **Leak in circuit:** A hole or break in the ventilator tubing. **Action: Inspect visually, replace if damaged.** 4. **Accidental extubation:** The ETT is partially or completely out. **Action: Immediate assessment—if the ETT is out, call for help, position patient upright, provide bag-valve-mask ventilation with 100% O2, prepare for emergent re-intubation.** **Never ignore alarms. Even if the patient looks "fine," an alarm indicates a problem that will worsen if not fixed.** **Manual Resuscitation (Bag-Valve-Mask) Bag:** **Keep a manual resuscitation bag at the bedside at all times.** If the ventilator fails (power loss, disconnection, malfunction), the patient must be immediately hand-ventilated while the problem is fixed. Technique: - Attach the bag to the ETT (or mask if extubated). - Attach supplemental oxygen (preferably 10–15 L/min) for high FiO2 delivery. - Squeeze the bag to deliver a breath (~600–700 mL volume) over 1–2 seconds; watch the chest rise. - Allow passive exhalation (do not squeeze while the patient exhales). - Ventilate at 12–16 breaths/min for adults. - Ensure the patient is oxygenated and calm while repairs/troubleshooting occur. **Suctioning—A Core Skill:** Suctioning removes secretions from the ETT and lower airways, maintaining a patent airway. **Guidelines for Safe Suctioning:** 1. **Suction only as needed**—not on a routine schedule (e.g., every 2 hours). Signs indicating need: audible crackles/rhonchi, high ventilator pressure alarm, visible secretions, or patient coughing. 2. **Hyperoxygenate before and after:** Increase FiO2 to 1.0 (100%) for 1–2 minutes before suctioning, suction, then return to baseline FiO2. This prevents hypoxemia during the procedure. 3. **Use proper technique:** - Use a sterile suction catheter (size 12–14 French for adults). - Gently advance the catheter down the ETT until resistance is felt (catheter at the carina), then pull back 1 cm. - Apply suction **only during withdrawal** (not while advancing), rotating the catheter gently. - Limit suctioning time to **10–15 seconds per pass**; longer durations risk hypoxemia. - Allow the patient to re-oxygenate (1–2 minutes) between passes. - Perform a maximum of 2–3 passes per suctioning episode unless minimal secretions are obtained. 4. **Monitor the patient:** Watch SpO2, heart rate, and ABG trends. If SpO2 drops >5%, stop suctioning and re-oxygenate. 5. **Infection control:** Use sterile technique to prevent ventilator-associated pneumonia (VAP). Wear gloves, mask, and eye protection if splash risk. **Ventilator-Associated Pneumonia (VAP) Prevention Bundle:** VAP is a **serious complication of mechanical ventilation** caused by aspiration of contaminated secretions into the lower airways. Prevention is a core nursing responsibility. **VAP Prevention Measures ("Big 4"):** 1. **Elevate the Head of Bed (HOB) to 30–45°:** - Reduces gastric reflux and aspiration of secretions pooled above the ETT cuff. - Check HOB angle regularly; patients tend to slide down, reducing the angle. - Contraindications: hemodynamic instability, recent abdominal surgery, spinal precautions (but even these can often accommodate some elevation). 2. **Daily Sedation Interruption and Spontaneous Breathing Trial (SBT):** - Daily, hold sedative/analgesic drugs, allow the patient to awaken, and assess readiness to breathe spontaneously. - If awake and cooperative, the patient can trigger breaths on pressure support (PS) alone for 30–120 minutes. - Benefits: Shorter duration of mechanical ventilation, reduced VAP risk, improved outcomes. - Criteria to assess readiness: Alert and cooperative (RASS ≥–2), PaO2/FiO2 ≥200, PEEP ≤5, no need for high vasopressor doses. - If the patient tolerates the SBT, plan extubation. - If the patient fails (RR >40, SpO2 drops, HR increases, diaphoresis), resume sedation and reassess in 24 hours. 3. **Oral Care (Chlorhexidine Rinse):** - Daily oral hygiene with **chlorhexidine 0.12% mouth rinse** (or saline if chlorhexidine contraindicated) reduces VAP incidence by ~40%. - Technique: Brush teeth gently, rinse with chlorhexidine, suction secretions. - Frequency: Every 12 hours. - Benefit: Reduces bacterial colonization of the oropharynx, reducing aspiration risk. 4. **Subglottic Secretion Drainage:** - Some ICU ventilators have a specialized ETT with a small lumen above the cuff that allows continuous or intermittent suction of secretions pooled in the subglottic space. - Reduces VAP incidence by reducing aspiration of these secretions. - If available, use routinely. **Additional VAP Prevention Strategies:** - **DVT/Stress-Ulcer Prophylaxis:** Prevent complications that lengthen ICU stay. DVT prophylaxis: compression stockings, early mobilization, pharmacological (LMWH, heparin). Stress-ulcer prophylaxis: H2-blocker (famotidine) or PPI (omeprazole). - **Early enteral nutrition:** Start feeding within 24–48 hours if patient is stable; maintains gut integrity and immune function. - **Hand hygiene:** Wash hands before and after patient contact; don latex gloves for secretion contact. Use alcohol-based hand rub if soap/water unavailable. - **Ventilator circuit management:** Drain condensation from the ventilator tubing into a drainage bag (not back into the circuit); replace circuit only if soiled or malfunctioning (not on a routine schedule). **Weaning from Mechanical Ventilation:** Weaning is the **gradual reduction of mechanical support** as the patient recovers and is able to breathe spontaneously. Premature weaning (extubating before ready) risks re-intubation; delayed weaning (keeping the patient on full support too long) prolongs ICU stay and VAP risk. **Weaning Criteria (Patient Must Meet ALL):** 1. **Adequate oxygenation:** PaO2/FiO2 >200 (on PEEP ≤5). 2. **Adequate ventilation:** pH >7.25, PaCO2 <50 mmHg (or baseline for COPD), minute ventilation <20 L/min. 3. **Respiratory drive:** RR <35 breaths/min, negative inspiratory force (NIF) <–20 cmH2O (patient can generate enough negative pressure to trigger a breath). 4. **Hemodynamic stability:** HR <120/min, systolic BP >90 mmHg (or on minimal vasopressor). 5. **Adequate mental status:** Alert, cooperative (RASS ≥–2); can follow commands. 6. **Absence of fever:** Temperature <38.5°C (fever suggests infection, which increases metabolic demand). 7. **Resolved underlying condition:** Pneumonia improving (infiltrates resolving, WBC declining), sepsis controlled (lactate down), pain/anxiety controlled. **Weaning Strategies:** 1. **Spontaneous Breathing Trial (SBT) on Pressure Support (PS):** Once daily (during sedation interruption), switch the patient to low PS (typically 5–8 cmH2O) with minimal PEEP (5 cmH2O), and allow the patient to breathe for 30–120 minutes. If the patient breathes comfortably without signs of distress (RR <35, SpO2 >90%, HR <120), the SBT is "passed," and extubation is planned. 2. **Synchronized IMV (SIMV) Weaning:** Gradually reduce the mandatory breath rate (e.g., 12 → 8 → 4 breaths/min), allowing the patient to assume more work. When mandatory rate is very low, essentially the patient is breathing spontaneously, and extubation is considered. 3. **Pressure Support Weaning:** Gradually reduce the pressure level (e.g., 25 → 15 → 10 → 5 cmH2O), requiring the patient to work harder with each reduction. When PS is very low (≤5 cmH2O), the patient is essentially breathing spontaneously. **Extubation:** Once weaning criteria are met and an SBT is successful: 1. **Pre-extubation:** Confirm that the underlying condition is resolving, medications (antibiotics, etc.) are optimized, and the airway is patent (no stridor). Suction the airway and oropharynx thoroughly. 2. **Extubation procedure:** - Deflate the ETT cuff by withdrawing air from the cuff balloon. - Quickly remove the ETT as the patient exhales (or during a cough). - Immediately apply supplemental oxygen (nasal cannula or mask) at the same FiO2 that the patient was on before extubation. - Monitor for signs of respiratory distress, stridor, or re-intubation need. 3. **Post-extubation monitoring:** Watch for laryngeal edema (stridor, hoarseness), hypoxemia, or respiratory muscle fatigue. If the patient cannot maintain oxygenation/ventilation or has severe stridor, rapid re-intubation may be needed. 4. **Re-intubation risk:** About 10–20% of extubated patients require re-intubation within 48 hours, especially if weaning criteria were marginal or underlying condition is not fully resolved. **Complications of Mechanical Ventilation:** - **Ventilator-associated pneumonia (VAP):** Bacterial pneumonia acquired in ventilated patients; high mortality; prevention is crucial. - **Sinusitis:** Bacterial infection of the paranasal sinuses, from prolonged nasal intubation. - **Tracheal stenosis:** Scarring and narrowing of the trachea from prolonged tube presence or cuff over-inflation. - **Laryngeal edema/hoarseness:** From tube trauma; usually temporary. - **Tube obstruction/malposition:** Can occur suddenly; requires immediate assessment. - **Barotrauma/volutrauma:** Lung rupture from excessive pressure/volume, causing pneumothorax. - **Ventilator-associated events (VAEs):** New/worsening oxygenation deterioration after improving, with increased ventilator parameters; marker of potential VAP or other complications. - **Delirium/anxiety:** Common in ICU; manage with appropriate sedation, sleep, early mobilization. - **Disuse atrophy:** Prolonged immobility and sedation cause muscle wasting; early mobilization and rehabilitation reduce this. **Nursing Documentation for Ventilator Patients:** Document every shift: - Ventilator settings (mode, Vt, RR, FiO2, PEEP). - Breath sounds (bilateral and equal? any wheezing/rhonchi?). - Capnography waveform and ETCO2 trend. - ABG values (if done) and trend. - Cuff pressure (if checked). - Secretion amount/character (clear, purulent, blood-tinged?). - Alarms and how addressed. - Patient responsiveness and tolerance (comfortable, fighting vent, requiring sedation adjustment?). - Skin integrity around ETT. - Daily SBT result (if performed). - VAP prevention bundle compliance (HOB angle, oral care, etc.).

The care of patients with acute respiratory failure, ARDS, and PE must be delivered within the **Philippine legal, ethical, and professional framework**. Understanding **RA 9173 (The Philippine Nursing Act of 2002)** and the **Nursing Competencies and Standards** is essential for NLE success and safe, ethical practice. **RA 9173: The Philippine Nursing Act of 2002** RA 9173 defines the **scope of nursing practice in the Philippines**, establishes professional standards, and governs the licensing and regulation of nurses by the Professional Regulation Commission (PRC) Board of Nursing. **Key Provisions Relevant to Respiratory Care:** 1. **Definition of Nursing:** Nursing is the practice of caring for the sick, the disabled, the aged, and other persons in need of health services in health, wellness, and illness care in the community and institutional setting. This encompasses the assessment, planning, implementation, and evaluation of care—the nursing process framework applied throughout this chapter. 2. **Scope of Practice - Core Functions:** - **Care (Caring):** Providing compassionate, holistic care. In respiratory failure, this means not only managing the ventilator and medications but also addressing the patient's fear, pain, and psychosocial needs. - **Cure (Curing/Treatment):** Implementing medical regimens, administering medications (anticoagulants, bronchodilators, antibiotics), and supporting medical interventions (intubation, mechanical ventilation, thrombolytics). - **Coordinate (Coordination):** Acting as the liaison among the multidisciplinary team (physicians, respiratory therapists, pharmacists, social workers, family). In an ICU managing a ventilated ARDS patient, the nurse coordinates communication about the patient's progress, weaning readiness, and discharge planning. - **Communicate (Communication):** Providing education to patients and families. Teaching a patient on warfarin about consistent vitamin-K intake, signs of bleeding, and drug interactions is core to nursing. 3. **Nursing Diagnosis and Analysis:** Nurses are **licensed to diagnose health problems and execute nursing care independently**. NANDA nursing diagnoses (e.g., Impaired gas exchange, Ineffective breathing pattern, Anxiety) are within the scope of nursing practice. The nurse recognizes these diagnoses through systematic assessment, plans interventions, implements them, and evaluates outcomes. 4. **Advocacy and Rights Protection:** Nurses are **advocates for patients' rights**, including the right to informed consent, privacy, dignity, and safe care. In respiratory failure, this includes advocating for: - **Timely intubation** if the patient is deteriorating despite non-invasive support. - **Appropriate pain and sedation management** (mechanically ventilated patients deserve comfort). - **Clear communication** about diagnosis, prognosis, and options (including goals of care—is the aim to pursue curative or comfort-focused care?). - **Family involvement** in decision-making, consistent with the patient's wishes and cultural values. 5. **Standards of Care:** Nurses must adhere to professional standards and evidence-based practice. For respiratory failure: - **ABG interpretation and trend analysis** are expected competencies. - **Ventilator management, alarm response, and VAP prevention** are standards of critical care nursing. - **Anticoagulation monitoring** (aPTT, INR, HIT screening) is a nursing responsibility. - **Documentation** of assessments, interventions, and outcomes is mandatory for accountability and continuity of care. 6. **Mandatory Reporting:** Nurses must report **adverse events, medication errors, and unsafe conditions** to the appropriate authority. If a patient is extubated prematurely and requires re-intubation, or if a medication error occurs (e.g., wrong anticoagulant dose leading to bleeding), the nurse has a professional and legal obligation to report it to ensure quality improvement and patient safety. **Philippine NCM (National Competency-Based Nursing Curriculum) Framework:** The **NCM** outlines the competencies expected at **different levels of nursing practice**: **NCM Level I (Basic/Entry-Level), NCM Level II (Intermediate), and NCM Level III (Advanced/Specialist)**. The NLE assesses NCM Level I competencies—what a newly registered nurse (with a BSN) must know and be able to do. **Respiratory Nursing Competencies (NCM Level I—NLE Scope):** 1. **Assessment Competencies:** - Obtain a focused respiratory history (onset, duration, type of dyspnea, pain, associated symptoms, risk factors). - Perform systematic physical examination: **observe respiratory rate, depth, use of accessory muscles, and posture; palpate for tactile fremitus and chest movement; percuss to detect hyperresonance/dullness; auscultate breath sounds bilaterally** (normal vesicular, adventitious crackles/wheezes/rhonchi). - Interpret ABG values: identify PaO2, PaCO2, pH, HCO3, and classify as Type I/II respiratory failure or ARDS. - Recognize early signs of hypoxaemia (restlessness, agitation, anxiety, tachycardia, tachypnea) and late signs (cyanosis, bradycardia, altered mental status). - Assess for DVT risk and signs (unilateral calf swelling, warmth, Homan's sign—though not sensitive). 2. **Diagnostic Competencies:** - Recognize when to order/anticipate: **ABG, chest X-ray, D-dimer, CTPA, ECG, pulse oximetry, capnography, troponin, BNP**. - Collaborate with the healthcare team to ensure timely and appropriate diagnostic tests. - Communicate findings to the physician (e.g., "Patient is increasingly restless with SpO2 dropping despite high-flow oxygen; ABG likely needed"). 3. **Nursing Diagnosis Competencies (NANDA Framework):** - Formulate accurate nursing diagnoses based on assessment data: - **Impaired gas exchange** related to V/Q mismatch, shunt, or diffusion impairment, as evidenced by hypoxaemia, tachypnea, restlessness. - **Ineffective breathing pattern** related to neuromuscular weakness, CNS depression, or increased work of breathing, as evidenced by tachypnea, use of accessory muscles, ABG abnormality. - **Anxiety** related to perceived threat to life (hypoxaemia/dyspnea), as evidenced by restlessness, expressed fear, tachycardia. - **Risk for thrombus/PE** related to immobility, surgery, malignancy, as evidenced by Virchow's triad factors. - Prioritize diagnoses using **Maslow's hierarchy**: physiological safety (oxygenation) is the top priority; psychological safety (anxiety/fear) is secondary. 4. **Planning and Goal-Setting Competencies:** - Establish **SMART goals** (Specific, Measurable, Achievable, Relevant, Time-bound): - Short-term goal: "Patient will achieve PaO2 >60 mmHg on room air and maintain SpO2 >90% within 4 hours." - Long-term goal: "Patient will resume activities of daily living independently without dyspnea within 7 days." - Involve the patient and family in goal-setting; consider their values and preferences. 5. **Implementation Competencies:** - **Oxygen therapy:** Know how to apply and titrate various devices (nasal cannula 1–6 L/min delivering ~24–44% FiO2, non-rebreather mask delivering ~95%, high-flow nasal cannula). - **Positioning:** Upright (sitting) position improves oxygenation by reducing abdominal pressure on the diaphragm and improving lung expansion. For unilateral lung disease (e.g., pneumonia), position the **good lung down** (side-lying) to maximize perfusion-ventilation matching (e.g., left-sided pneumonia → position on right side). - **Breathing exercises:** Teach deep breathing (slow, full diaphragmatic breaths), pursed-lip breathing (for COPD, slows exhalation and maintains airway pressure), and coughing to mobilize secretions. - **Airway clearance:** Suction secretions, encourage coughing, position upright, mobilize patient, and consider chest physiotherapy. - **Medication administration:** Administer bronchodilators, corticosteroids, antibiotics, anticoagulants (with understanding of dose, route, monitoring parameters, and adverse effects). - **Mechanical ventilation care:** Secure and monitor the ETT, respond to alarms, suction, implement VAP prevention, maintain cuff pressure, and support weaning. - **Anticoagulation monitoring:** Draw blood for aPTT/INR at appropriate intervals, interpret results, communicate to physician, and educate patient on signs of bleeding and medication adherence. - **Prevention:** Implement DVT prophylaxis (compression stockings, early ambulation, pharmacological), PE prevention, and VAP prevention measures. 6. **Evaluation Competencies:** - Continuously assess the effectiveness of interventions: - "Has dyspnea improved? Is the patient more comfortable?" - "Are ABG values trending in the right direction?" - "Is the patient tolerating mechanical ventilation (fighting less, oxygenation improving)?" - "Has anticoagulation been therapeutic without bleeding complications?" - Modify the care plan based on evaluation; escalate to the physician if the patient is not progressing as expected. **Ethical Principles in Respiratory Care (RA 9173 & Professional Ethics):** 1. **Beneficence (Doing Good):** Provide interventions that benefit the patient (e.g., supplemental oxygen, anticoagulation, mechanical ventilation support). 2. **Non-Maleficence (Avoiding Harm):** Prevent complications (e.g., avoid excessive oxygen that causes toxicity, avoid barotrauma from high PEEP, prevent VAP, avoid medication errors in anticoagulation). 3. **Autonomy (Respect for Self-Determination):** Ensure informed consent for intubation, mechanical ventilation, anticoagulation, and other interventions. Even in critical illness, the patient's wishes and values guide decisions. If the patient is unable to communicate (sedated/paralyzed), involve the family in shared decision-making. 4. **Justice (Fair Distribution of Resources):** In a resource-limited Philippine healthcare setting, allocate ICU beds and mechanical ventilators fairly. For example, if an ARDS patient is not improving after weeks of ventilation and is unlikely to survive, and another patient with reversible ARDS is waiting for a ventilator, thoughtful ethical discussions about resource allocation are necessary. **Culturally Sensitive Care in Philippine Context:** Philippine society values **family involvement, respect for elders, and religious faith**. When caring for a respiratory failure patient: - **Involve the family early** in discussions about diagnosis, treatment options, and goals of care. The family is often the primary decision-maker. - **Respect cultural practices:** Some patients may wish to see a priest/imam; allow religious rituals and spiritual support. - **Use simple, clear language** (Tagalog or the patient's preferred language if possible) to explain technical concepts like "airway," "oxygenation," and "ventilator." - **Acknowledge the emotional burden** on the family; provide compassionate support and regular updates. **Quality and Safety in Philippine Healthcare Settings:** Managing respiratory failure in Philippine hospitals—whether in a tertiary referral center with ICU resources or a provincial facility with limited equipment—requires: 1. **Vigilance with Limited Resources:** If a mechanical ventilator is not available, escalate to a referral center early; do not delay transfer hoping for improvement. 2. **Infection Prevention:** VAP, ventilator-associated sinusitis, and other secondary infections are serious; strict adherence to asepsis is critical, especially in settings with limited microbiology surveillance. 3. **Documentation and Communication:** Clear, timely handover communication among nursing shifts and teams reduces errors. Document ABG trends, ventilator settings, alarm incidents, and patient responses. 4. **Error Reporting and Learning:** If an error occurs (e.g., wrong anticoagulant dose, delayed recognition of respiratory failure), report it through the hospital's incident reporting system without fear of punishment (a "just culture" approach). This promotes quality improvement. **Continuing Professional Development:** RA 9173 requires nurses to engage in **continuing professional development** to maintain and advance competency. For respiratory nursing: - **In-service training on ventilator management, ABG interpretation, and VAP prevention** should be regularly available. - **Simulation and skills labs** for managing respiratory emergencies (intubation, bag-valve-mask ventilation, extubation). - **Journal clubs and case reviews** to discuss complex cases and latest evidence. - **Certification in critical care nursing or respiratory nursing** (through recognized Philippine organizations) demonstrates advanced competency.